Hemispherx Announces Biosecurity Program to Potentially Reduce Pandemic Influenza Threat
August 26, 2013 08:00 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Aug. 26, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE:HEB) announced that at the 2nd International Conference on Biodefense and Natural Disasters meeting in Orlando, FL on August...
PositiveID Corporation Receives Nucleic Acids From the CDC Influenza Division to Develop a Diagnostic Assay to Detect H5N1 Avian Flu
March 28, 2012 08:29 ET
|
PositiveID Corporation
DELRAY BEACH, Fla., March 28, 2012 (GLOBE NEWSWIRE) -- PositiveID Corporation ("PositiveID" or "Company") (OTCBB:PSID), an emerging growth company and developer of advanced technologies for diabetes...
PositiveID Corporation Expands Its Biological Detection Capabilities to Address Avian Flu and Other Pandemic Viruses
September 14, 2011 16:30 ET
|
PositiveID Corporation
DELRAY BEACH, Fla., Sept. 14, 2011 (GLOBE NEWSWIRE) -- PositiveID Corporation ("PositiveID" or the "Company") (OTCBB:PSID), a developer of medical technologies for diabetes management, clinical...
Hemispherx Biopharma Receives U.S. Patent Office Notification of New Patent Granted for the Use of Ampligen(R) as an Influenza Virus Vaccine Adjuvant for Protection Against Pandemic Avian Influenza
July 19, 2011 08:00 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, July 19, 2011 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company" or "Hemispherx") today announced the granting of a new United States Patent for the use of...